Mankind Pharma Ltd
Healthcare
Flashback 2024: Top healthcare deals of the year
Dealmaking activity in India’s healthcare sector remained strong this year with several foreign private equity firms ......
General
Flashback 2024: Check out the top M&As of the year
The merger and acquisition (M&A) activity in India strengthened during 2024 compared with last year, with technology, ......
Healthcare
ChrysCapital, LP co-investors set stage for nearly $800-mn exit
ChrysCapital, which hit the milestone of raising the largest-ever sector-agnostic private equity fund focused on India ......
Healthcare
IT Dept conducts searches at PE-backed Mankind Pharma a day after listing
The income tax department is conducting searches at Mankind Pharma Ltd's office in New Delhi, two government sources......
Healthcare
Mankind Pharma valuation nears $7 bn as shares jump on listing
Shares of Manforce condom maker Mankind Pharma Ltd surged as much as 32% in its first session on Tuesday, valuing ......
Finance
The year of caution for anchor investors after a bloody 2021
Primary markets are poised to cool further this year as anchor investors who burnt their fingers in new-age technology ......
General
Grapevine: Byju's rakes in $700 mn at flat valuation; Megha Engineering concludes Lanco Anpara deal
Edtech major Byju’s has raised $700 million at a flat valuation of $22 billion, involving two separate deals of equity......
Healthcare
Analysis: M&A deal value in healthcare and pharma hits record high in Jan-June
Merger and acquisitions (M&As) deal value in the healthcare and pharmaceutical space hit a record high in Jan-June, crossing...
Healthcare
ChrysCapital set to reinvest in another pharmaceutical portfolio firm
Homegrown private equity firm ChrysCapital is in advanced talks to increase its stake in its oldest pharmaceutical portfolio company,...
Healthcare
PE deal of the month: ChrysCap backs Mankind in biggest-ever India healthcare bet
In an otherwise lean month of deal-making, domestic private equity major ChrysCapital’s decision to reinvest in Mankind Pharma, barely three ......









